Evidence map›Paper›PMID 28913902›Full record

ArticleGenetic epidemiology2017

Analysis of cancer gene expression data with an assisted robust marker identification approach.

Hao Chai, Xingjie Shi, Qingzhao Zhang, Qing Zhao, Yuan Huang, Shuangge Ma

Abstract read
In one paragraph

Article in Genetic epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Integration of Proteomics and Other Omics Data.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  8. Integration strategies of multi-omics data for machine learning analysis.Computational and structural biotechnology journal · 2021
    Review
  9. Structured Analysis of the High-dimensional FMR Model.Computational statistics & data analysis · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hao ChaiDepartment of Biostatistics, Yale University, New Haven, Connecticut, United States of America.
Xingjie ShiDepartment of Statistics, Nanjing University of Finance and Economics, Nanjing Shi, Jiangsu Sheng, China.
Qingzhao ZhangSchool of Economics, Wang Yanan Institute for Studies in Economics, Xiamen University, Xiamen Shi, Fujian Sheng, China.
Qing ZhaoMerck Research Laboratories, Rahway, New Jersey, United States of America.
Yuan HuangDepartment of Biostatistics, Yale University, New Haven, Connecticut, United States of America.
Shuangge MaDepartment of Biostatistics, Yale University, New Haven, Connecticut, United States of America.ORCID 0000-0001-9001-4999

Funding

Novel methods for identifying genetic interactions in cancer prognosisR01CA204120 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2016 to 2026
$3.5M
Penalization methods for identifying gene envrionment interactions and applications to melanoma and other cancer typesR21CA191383 · NCI · YALE UNIVERSITY · PI MA, SHUANGGE · 2015 to 2017
$435k
Development of Integrated Analysis Methods and Applications to TCGA dataR03CA182984 · NCI · YALE UNIVERSITY · PI MA, SHUANGGE · 2014 to 2015
$167k
NCI NIH HHS R01 CA204120NCI NIH HHS R03 CA182984NCI NIH HHS R21 CA191383
6 · The paper itself

Abstract

Gene expression (GE) studies have been playing a critical role in cancer research. Despite tremendous effort, the analysis results are still often unsatisfactory, because of the weak signals and high data dimensionality. Analysis is often further challenged by the long-tailed distributions of the outcome variables. In recent multidimensional studies, data have been collected on GEs as well as their regulators (e.g., copy number alterations (CNAs), methylation, and microRNAs), which can provide additional information on the associations between GEs and cancer outcomes. In this study, we develop an ARMI (assisted robust marker identification) approach for analyzing cancer studies with measurements on GEs as well as regulators. The proposed approach borrows information from regulators and can be more effective than analyzing GE data alone. A robust objective function is adopted to accommodate long-tailed distributions. Marker identification is effectively realized using penalization. The proposed approach has an intuitive formulation and is computationally much affordable. Simulation shows its satisfactory performance under a variety of settings. TCGA (The Cancer Genome Atlas) data on melanoma and lung cancer are analyzed, which leads to biologically plausible marker identification and superior prediction.

Indexed as

Models, GeneticBiomarkers, TumorGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMelanomaNeoplasmsPhenotypeSkin NeoplasmsBiomarkers, Tumorassisted analysiscancergene expressionrobustness

Identifiers

PMID28913902
PMCPMC5912176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.